Table of Contents
1 Table Of Contents
1.1 List of Tables
1.2 List of Figures
2 Executive Summary
2.1 Global Antidepressant Market Witnesses Moderate Growth
2.2 Antidepressants Remain the Mainstay of Mood Disorder Treatment, Despite Their Limitations
2.3 Leading Antidepressants in the Market
3 Antidepressants Market to 2018: Introduction
3.1 GBI Research Report Guidance
4 Market Overview
4.1 Introduction
4.2 Classification of Antidepressants
4.2.1 Selective Serotonin Reuptake Inhibitors
4.2.2 Serotonin-Norepinephrine Reuptake Inhibitors
4.2.3 Noradrenergic and Specific Serotonergic Antidepressants
4.2.4 Norepinephrine Reuptake Inhibitors
4.2.5 Norepinephrine-Dopamine Reuptake Inhibitors
4.2.6 Norepinephrine-Dopamine Disinhibitors
4.2.7 Serotonin Antagonist and Reuptake Inhibitors
4.2.8 Tricyclic Antidepressants
4.2.9 Tetracyclic Antidepressants
4.2.10 Monoamine Oxidase Inhibitors
4.2.11 Others
4.3 Adverse Effects
4.4 Major Marketed Products in the Antidepressants Therapy Area
4.5 Future Developments
4.6 Revenue
4.7 Annual Cost of Therapy
4.8 Treatment Usage Patterns
4.8.1 Diseased Population
4.8.2 Diagnosed Population
4.8.3 Prescription Population
4.9 Drivers and Restraints of the Antidepressants Market
4.9.1 Drivers
4.9.1.1 Increase in Prevalence Leads to Rise in Patient Population
4.9.1.2 Novel Multimodal Therapies Can Change the Future Market Scenario
4.9.1.3 Unmet Clinical Needs Pose a Steady Opportunity for R&D Initiatives and Growth of Existing Therapies
4.9.1.4 Increase in Awareness Levels of Disease States and Etiology, and Social Changes
4.9.2 Restraints
4.9.2.1 Low Diagnosis and Prescription Rates
4.9.2.2 Non-Pharmacological Therapies Preferred over Pharmacological Therapies
4.9.2.3 Poor Efficacy and Safety Profiles Restrain Usage
4.9.2.4 Repeated Drug Failures in Clinical Trials Has Put Substantial Pressure on Companies in This Area
4.9.2.5 Availability of Generics and Weak Pipeline
5 Therapeutic Landscape
5.1 Antidepressants Market for Major Depressive Disorder
5.1.1 Introduction
5.1.2 Revenue and Forecasts
5.1.3 Annual Cost of Therapy
5.1.4 Treatment Usage Patterns
5.1.4.1 Diseased Population
5.1.4.2 Diagnosed Population
5.1.4.3 Prescription Population
5.1.5 Geographical Segmentation
5.1.5.1 The US
5.1.5.2 EU5
5.1.5.3 Japan
5.1.6 Drivers and Restraints for the Antidepressants Market for Major Depressive Disorder
5.1.7 Drivers
5.1.7.1 New Launches
5.1.7.2 Improvements in Awareness and Resultant Diagnosis Levels Will Drive the Market
5.1.7.3 Substantial Unmet Need Increases Market Potential
5.1.8 Restraints
5.1.8.1 Noncompliance with Drug Therapy and Antidepressant Side Effects
5.1.8.2 Poor Diagnostic Tools for the Treatment of Major Depressive Disorder
5.1.8.3 Limitations in the Efficacy of Existing Drugs Can Potentially Lead to Low Prescription Rates
5.1.8.4 Inadequate Knowledge of Disease Progression Hinders Development of Drugs with Better Efficacy
5.1.8.5 Genericization Leading to a Decline in the Annual Cost of Therapy
5.1.8.6 Alternative Therapy for MDD
5.2 Antidepressants Market for Obsessive-Compulsive Disorder
5.2.1 Introduction
5.2.2 Revenue and Forecasts
5.2.3 Annual Cost of Therapy
5.2.4 Treatment Usage Patterns
5.2.4.1 Diseased Population
5.2.4.2 Diagnosed Population
5.2.4.3 Prescription Population
5.2.5 Geographical Segmentation
5.2.5.1 The US
5.2.5.2 EU5
5.2.5.3 Japan
5.2.6 Drivers and Restraints for the Antidepressants Market for Obsessive-Compulsive Disorder
5.2.7 Drivers
5.2.7.1 Scope for New Entrants — Novel Multimodal Therapies Can Change the Future Market Scenario
5.2.7.2 Chronic Nature of the Condition
5.2.7.3 More Active Treatment-Seeking Behavior to Drive Increase in Patient Volumes
5.2.8 Restraints
5.2.8.1 Problems with Diagnosis Hinder Market Growth
5.2.8.2 Poor Efficacy and Lack of Treatment Options
5.3 Antidepressants Market for Generalized Anxiety Disorder
5.3.1 Introduction
5.3.2 Revenue and Forecasts
5.3.3 Annual Cost of Therapy
5.3.4 Treatment Usage Patterns
5.3.4.1 Diseased Population
5.3.4.2 Diagnosed Population
5.3.4.3 Prescription Population
5.3.5 Geographical Segmentation
5.3.5.1 The US
5.3.5.2 EU5
5.3.5.3 Japan
5.3.6 Drivers and Restraints for the Antidepressants Market for Generalized Anxiety Disorder
5.3.7 Drivers
5.3.7.1 High Prevalence
5.3.7.2 Unmet Needs Related to Safety and Efficacy
5.3.8 Restraints
5.3.8.1 Poor Diagnosis Rates
5.3.8.2 Psychotherapy Preferred over Pharmacotherapy
5.4 Antidepressants Market for Panic Disorder
5.4.1 Introduction
5.4.2 Revenue and Forecasts
5.4.3 Annual Cost of Therapy
5.4.4 Treatment Usage Patterns
5.4.4.1 Diseased Population
5.4.4.2 Diagnosed Population
5.4.4.3 Prescription Population
5.4.5 Geographical Segmentation
5.4.5.1 The US
5.4.5.2 EU5
5.4.5.3 Japan
5.4.6 Drivers and Restraints for the Antidepressants Market for Panic Disorder
5.4.7 Drivers
5.4.7.1 Growing Prevalence
5.4.7.2 Unmet Needs Related to Safety and Efficacy
5.4.8 Restraints
5.4.8.1 Lack of Awareness and Problems with Diagnosis
5.4.8.2 Low Prescription Rates
5.4.8.3 Safety and Efficacy Issues
6 Geographical Landscape
6.1 The US
6.1.1 Revenue and Forecasts
6.1.2 Annual Cost of Therapy
6.1.3 Treatment Usage Patterns
6.1.3.1 Diseased Population
6.1.3.2 Diagnosed Population
6.1.3.3 Prescription Population
6.2 EU5
6.2.1 Revenue and Forecasts
6.2.2 Annual Cost of Therapy
6.2.3 Treatment Usage Patterns
6.2.3.1 Diseased Population
6.2.3.2 Diagnosed Population
6.2.3.3 Prescription Population
6.3 Japan
6.3.1 Revenue and Forecasts
6.3.2 Annual Cost of Therapy
6.3.3 Treatment Usage Patterns
6.3.3.1 Diseased Population
6.3.3.2 Diagnosed Population
6.3.3.3 Prescription Population
7 Pipeline Analysis
7.1 Introduction
7.2 Summary of the Current Antidepressants R&D Pipeline
7.3 Profiles of Key Late-Stage Drugs in the Antidepressants Market
7.3.1 Vortioxetine (Lu AA21004)
7.3.1.1 Overview
7.3.1.2 Mechanism of Action
7.3.1.3 R&D Progress/Latest Activity
7.3.1.4 Clinical Trial Summaries
7.3.1.5 Licensing and Collaboration
7.3.2 F-2695 (levomilnacipran)
7.3.2.1 Overview
7.3.2.2 Mechanism of Action
7.3.2.3 R&D Progress/Latest Activity
7.3.3 LY-2216684 (edivoxetine)
7.3.3.1 Overview
7.3.3.2 Mechanism of Action
7.3.3.3 R&D Progress/Latest Activity
7.3.4 OPC-34712
7.3.4.1 Overview
7.3.4.2 Mechanism of Action
7.3.4.3 R&D Progress/Latest Activity
7.3.5 EB-1010/Amitifadine
7.3.5.1 Overview
7.3.5.2 Mechanism of Action
7.3.5.3 R&D Progress/Latest Activity
7.3.6 PNB01
7.3.6.1 Overview
7.3.6.2 Mechanism of Action
7.3.6.3 R&D Progress/Latest Activity
8 Competitive Landscape
8.1 Competitive Profiling
8.1.1 H. Lundbeck
8.1.1.1 Company Overview
8.1.1.2 Business Description
8.1.1.3 Financial Overview
8.1.1.4 SWOT profile
8.1.2 AstraZeneca
8.1.2.1 Company Overview
8.1.2.2 Business Description
8.1.2.3 SWOT Profile
8.1.3 Eli Lilly and Company
8.1.3.1 Company Overview
8.1.3.2 Business Description
8.1.3.3 Financial Overview
8.1.3.4 SWOT Profile
8.1.4 Forest Laboratories
8.1.4.1 Company Overview
8.1.4.2 Business Description
8.1.4.3 Financial Overview
8.1.4.4 SWOT Profile
8.1.5 Pfizer Inc.
8.1.5.1 Company Overview
8.1.5.2 Business Description
8.1.5.3 Financial Overview
8.1.5.4 SWOT Profile
8.1.6 GlaxoSmithKline
8.1.6.1 Company Overview
8.1.6.2 Business Description
8.1.6.3 Financial Overview
8.1.6.4 SWOT Profile
8.1.7 Bristol-Myers Squibb Company
8.1.7.1 Company Overview
8.1.7.2 Business Description
8.1.7.3 Financial Overview
8.1.7.4 SWOT Profile
9 Strategic Consolidations
9.1 Merger and Acquisition Deals
9.1.1 Paladin Labs Completes Acquisition of Labopharm
9.1.2 High River Acquires 6.5% Stake in Forest Laboratories
9.1.3 Forest Laboratories Completes Acquisition of Clinical Data
9.1.4 Azur Pharma Completes Merger with Jazz Pharmaceuticals in All Stock Transaction
9.1.5 Nuvo Research Acquires ZARS Pharma
9.1.6 Sun Pharmaceutical Acquires Remaining 24% Stake of Caraco Pharmaceutical
9.2 Licensing Agreements
9.2.1 Labopharm Enters into Licensing Agreement with Angelini Group for OLEPTRO
9.2.2 Omeros Expands Licensing Agreement with Daiichi Sankyo
9.2.3 Jazz Pharmaceuticals Enters into Sub-Licensing Agreement with Anchen
9.2.4 AstraZeneca Enters into Collaboration and Licensing Agreement with Targacept
9.2.5 Indevus Pharmaceuticals Enters into Licensing Agreement with Teva Pharmaceutical
9.2.6 Impax Laboratories Enters into Licensing Agreement with Wyeth
9.2.7 Mylan Enters into Licensing Agreement with GlaxoSmithKline
9.2.8 Tikvah Therapeutics Signs Licensing Agreement with Therapade Technologies
9.2.9 GlaxoSmithKline Signs an Agreement with Fabre-Kramer Pharmaceuticals
9.2.10 Jazz Pharmaceuticals Enters into Licensing Agreement with Solvay
9.2.11 Targacept Enters into Licensing Agreement with Yale University
9.3 Co-Development Deals
9.3.1 Lundbeck Enters into Co-Development Agreement with Otsuka Pharmaceutical
9.3.2 Eli Lilly Terminates Co-Development Agreement with Boehringer Ingelheim
9.3.3 Lundbeck Enters into Co-Development Agreement with Takeda
10 Antidepressants Market: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Primary Research
10.4 Therapeutic Landscape
10.4.1 Epidemiology-based Forecasting
10.4.2 Market Size by Geography
10.5 Geographical Landscape
10.6 Pipeline Analysis
10.7 Competitive Landscape
10.7.1 Expert Panel Validation
10.8 Contact Us
10.9 Sources
10.10 Disclaimer